Bone health in multiple sclerosis

被引:0
作者
J. C. Gibson
G. D. Summers
机构
[1] Royal Derby Hospital,Level 2, Department of Rehabilitation Medicine
[2] Royal Derby Hospital,Department of Rheumatology
来源
Osteoporosis International | 2011年 / 22卷
关键词
Bone mineral density; Corticosteroids; Falls; Fractures; Multiple sclerosis; Vitamin D;
D O I
暂无
中图分类号
学科分类号
摘要
People who are disabled with multiple sclerosis (MS) may be at increased risk of osteoporosis. This review discusses issues relevant to bone health in MS and makes practical recommendations regarding prevention and screening for osteoporosis and fracture risk in MS. A search of the literature up until 5 April 2011 was performed using key search terms, and articles pertinent to bone health in MS were analysed. Bone mineral density (BMD) is reduced at the lumbar spine, hip and total body in MS, with the degree of reduction being greatest at the hip. A strong relationship exists between the disability level, measured by the Expanded Disability Status Score, and BMD at the lumbar spine and femoral neck, particularly the latter. The rate of loss of BMD also correlates with the level of disability. Pulsed corticosteroids for acute episodes of MS, even with a high cumulative steroid dose, do not significantly affect BMD, but an effect on fracture risk is yet to be elucidated. There appears to be no correlation between vitamin D levels and BMD, and the relationship between disability and vitamin D levels remains unclear. Falls and fractures are more common than in healthy controls, and the risk rises with increasing levels of disability. The principal factor resulting in low BMD and increased fracture risk in MS is immobility. Antiresorptive therapy with bisphosphonates and optimising vitamin D levels are likely to be effective interventions although there are no randomised studies of this therapy.
引用
收藏
页码:2935 / 2949
页数:14
相关论文
共 456 条
[1]  
Compston A(2008)Multiple sclerosis Lancet 372 1502-1517
[2]  
Coles A(2002)Osteoporosis in multiple sclerosis patients treated with corticosteroids Mult Scler 8 S79-1165
[3]  
Havrdova E(2002)Bone loss in women with multiple sclerosis International Journal of MS Care 4 3-604
[4]  
Tyblova M(1998)Fracture history and bone loss in patients with MS Neurology 51 1161-313
[5]  
Stepan JJ(2003)Bone status in multiple sclerosis: beyond corticosteroid Mult Scler 9 600-133
[6]  
Zikan V(2005)Vitamin D deficiency and reduced bone mineral density in multiple sclerosis: effect of ambulatory status and functional capacity J Bone Miner Metab 23 309-556
[7]  
Horakova D(1997)Reduced bone mass and fat-free mass in women with multiple sclerosis: effects of ambulatory status and glucocorticoid use Calcif Tissue Int 61 129-1264
[8]  
Ticha V(2005)Long-term effects of intravenous high dose methylprednisolone pulses on bone mineral density in patients with multiple sclerosis Eur J Neurol 12 550-4928
[9]  
Novakova I(2010)Changes in bone mineral density and bone metabolism markers in premenopausal women with multiple sclerosis and the relationship to clinical variables J Clin Neurosci 17 1260-1692
[10]  
Gallagher E(2004)Immediate fall of bone formation and transient increase of bone resorption in the course of high-dose, short-term glucocorticoid therapy in young patients with multiple sclerosis J Clin Endocrinol Metab 89 4923-175